BIIB Biogen presents phase 2 celia data at aaic demonstrating meaningful clinical outcomes and robust Tau reduction with diranersen in early
BIIB Biogen presents phase 2 celia data at aaic demonstrating meaningful clinical outcomes and robust Tau reduction with diranersen in early alzheimer’s disease Biogen - to advance diranersen into confirmatory phase 3 development
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.